Across TCGA pan-cancer cohorts, ARL14EP mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ARL14EP data layer compared with 22 for mass-spec protein and 3 for mutation status.
The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ARL14EP mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ARL14EP expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.
CCRCC, LSCC, and LUAD are the cancer types where ARL14EP mass-spec protein most reproducibly stratifies survival.